* ACELYRIN Inc reported a quarterly adjusted loss of 49 cents per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of -87 cents. The mean expectation of seven analysts for the quarter was for a loss of 80 cents per share. Wall Street expected results to range from $-1.08 to -57 cents per share.
* Reported revenue was zero; analysts expected zero.
* ACELYRIN Inc's reported EPS for the quarter was a loss of 49 cents.
* The company reported a quarterly loss of $48.55 million.
* ACELYRIN Inc shares had risen by 19.3% this quarter and lost 21.2% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by about 5.5% in the last three months.
* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," 3 "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology & medical research peer group is also "buy"
Wall Street's median 12-month price target for ACELYRIN Inc is $9.00 This summary was machine generated from LSEG data November 14 at 04:16 a.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Sep. 30 2024 -0.80 -0.49 Beat
Jun. 30 2024 -0.75 -0.86 Missed
Mar. 31 2024 -0.98 -0.36 Beat
Dec. 31 2023 -0.99 -0.97 Beat
Comments